Teva-Teriparatide Injection · DIN 02486423 · 250 mcg/mL · injection solution-2.4mL pre-filled pen
Limited Use, Reason for Use code 676 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 676 required
Write on scriptReason for Use code 676 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 676
Reason for Use code 676
For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria:
- 65 years of age or older; AND
- Has a documented bone mineral density [BMD] T-score of less than or equal to -3; AND
- Has a history of prior fragility fracture(s); AND
- Has used an anti-resorptive agent for osteoporosis which resulted in osteonecrosis of the jaw and/or an atypical femur fracture.
Note: The maximum lifetime exposure to teriparatide for an individual patient is 24 months
Coverage limit:
LU Authorization Period: 2 years
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Teriparatide
Brand(s): Forteo and generics
DOSAGE FORM/ STRENGTH: Please refer to the ODB Formulary for a list of funded
products
Effective with the May 31, 2024 Ontario Drug Benefit Formulary/ Comparative Drug Index
update, Teriparatide as Forteo has transitioned to the ODB formulary with its generic
versions. Also, please note that the Teriparatide biosimilar (Osnuvo) is also publicly
funded as a limited use benefit on the Ontario Drug Benefit formulary effective on
September 29, 2022. Refer to the ODB formulary for the Limited Use Criteria for all
teriparatide products.
401
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 401, record 230, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Teva-Teriparatide Injection · DIN 02486423
Manufacturer: Teva Canada Limited; listing date 2020-07-31
Health Canada: Marketed since 2020-07-08 · brand TEVA-TERIPARATIDE INJECTION · ATC H05AA02 TERIPARATIDE · form Solution · route Subcutaneous · ingredients TERIPARATIDE (TERIPARATIDE ACETATE) 250 MCG/ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Teriparatide Injection: Formulary list price $535.47 per unit (the source does not state the unit; exact figure $535.4700). What the ministry pays, not the patient.
Ministry pays: $535.4700 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02486423)
Source record
DIN 02486423: Teva-Teriparatide Injection
Raw flags: sec12=Y, sec3=Y
Item: 682400014; group id 788; item number 1918; lccId 00392; manufacturer id TEV
Source form: Inj Sol-2.4mL Pref Pen; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $535.4700; ministry $535.4700
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02486423
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97663
Interchangeable products
Apo-Teriparatide Injection · DIN 02498804 · $535.4700
Forteo · DIN 09857535 · $535.4700
Shortage status: resolved shortage (ended February 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02486423
Shortage record checked October 6, 2026